Neuropathic Pain Clinical Trial
— GHOSTOfficial title:
Is Mental Motor Imagery Training Using "GHOST", a Novel BCI-VR Feedback System (Brain Computer Interface and Virtual Reality) Efficient and Safe for Pain Relief in Phantom Limb Pain After Upper Limb Amputation or Brachial Plexus Lesion
NCT number | NCT03889353 |
Other study ID # | RC17_0417 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 9, 2019 |
Est. completion date | November 9, 2021 |
Verified date | April 2022 |
Source | Nantes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pilot Interventional study with minimal risks and constraints, prospective, monocentric. Safety and Efficacity evaluation of a Novel Medical Device.
Status | Completed |
Enrollment | 7 |
Est. completion date | November 9, 2021 |
Est. primary completion date | May 9, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Neuropathic pain / Phantom limb pain - Mean pain score >3 centimeter - Permanent pain - If Plexus Brachial injury : > 6 month - If Amputation : at least at wrist level - Motor and Sensory deficit : complete or incomplete - Informed consent - Public Health Insurance Exclusion Criteria: - MRI contraindication - Subject included in another interventional study - Pregnant women - Majors under guardianship or curatorship or safeguard of justice - History of associated head injury or any other neurological pathology altering the sensorimotor cerebral system or cognitive abilities and higher functions. - Presence of other lesions of the peripheral nervous system that may induce associated neuropathic pain. - Head trauma associated altering somatosensory system or cognitive abilities and higher functions |
Country | Name | City | State |
---|---|---|---|
France | Nantes Uh | Nantes |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital | Fondation Apicil |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of BCI intervention on mean daily pain | Determination by curve fitting technique (regression analysis) of the peak effect and calculation of the rate of improvement: success if> 30% | month 6 | |
Secondary | Evaluate the effectiveness of the BCI intervention on paroxysmal pains | duration of the paroxysmal pains | 60 days from day -30 to day + 30 , once a week from Month 1 to month 6 | |
Secondary | Evaluate the effectiveness of the BCI intervention on paroxysmal pains | the intensity of paroxysmal pains This scale measures the intensity of paroxysmal pain. It is a self-assessment. Scores measured with Visual Analog Score.
The scale is graded from 0 (no pain) to 10 (most intense pain the patient can imagine). The value 10 (maximum) is the worst result. There is no combination of sub-ranges to compute the score |
60 days from day -30 to day + 30 , once a week from Month 1 to month 6 | |
Secondary | Evaluate the effectiveness of the BCI intervention on paroxysmal pains | the frequency of paroxysmal pains | 60 days from day -30 to day + 30 , once a week from Month 1 to month 6 | |
Secondary | Evaluate the effect of the intervention on quality of life: SF36 | SF36 Questionnaire quality of life For each question, an algorithm allows the calculation of scores to obtain a number between 0 (zero quality - worse outcome) and 100 (maximum quality). | Day 1, 12, 90, 180 | |
Secondary | Evaluate the effect of the intervention on anxiety and depression | HAD questionnaire : Hospital Anxiety and Depression scale It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), resulting in two scores (maximum score of each score = 21).
To detect anxious and depressive symptoms, the following interpretation can be proposed for each of the scores (A and D): 7 or less: lack of symptomatology 8 to 10: doubtful symptomatology - 11 and more: definite symptomatology. |
Day 1, 12, 90, 180 | |
Secondary | evaluating cortical plasticity | MRI analysis the physiopathological mechanisms governing phantom pain | Day 1, 12, 30 | |
Secondary | evaluating cortical plasticity | EEG analysis the physiopathological mechanisms governing phantom pain | Day 1, 12, 30 | |
Secondary | Evaluate the performance of subjects to control the neurofeedback system | Motor Imagery Questionnaire | Day 1, 12, 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 | |
Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 |